<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781972</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00276357</org_study_id>
    <nct_id>NCT04781972</nct_id>
  </id_info>
  <brief_title>Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD</brief_title>
  <official_title>Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' goal is to develop neuroimaging biomarkers to predict response to&#xD;
      treatment with methylphenidate, which then can be used in the development of novel&#xD;
      pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall&#xD;
      objective of this study is to measure the changes in task-related neural activity related to&#xD;
      symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by&#xD;
      magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will&#xD;
      be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants&#xD;
      will complete neuropsychological testing along with fMRI and MRS scans after a single dose of&#xD;
      each treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a double-blind cross over of a single dose of methylphenidate (10mg or 15mg) and matching placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD signal during response inhibition</measure>
    <time_frame>Approximately 90 minutes after dose</time_frame>
    <description>BOLD signal (brain activity during fMRI, arbitrary units) in the anterior cingulate cortex during response inhibition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glutamate level in the anterior cingulate cortex</measure>
    <time_frame>Approximately 2 hours after dose</time_frame>
    <description>Glutamate level (measured by MRS, institutional units) in the anterior cingulate cortex.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ADHD - Combined Type</condition>
  <arm_group>
    <arm_group_label>Methylphenidate first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>single dose of 10 mg or 15 mg</description>
    <arm_group_label>Methylphenidate first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Methylphenidate first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  right handed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
&#xD;
          -  past or current neurological disorder&#xD;
&#xD;
          -  non-ADHD cause of cognitive impairment&#xD;
&#xD;
          -  uncontrolled medical disorder&#xD;
&#xD;
          -  head trauma with loss of consciousness in the last year or any evidence of functional&#xD;
             impairment due to and persisting after head trauma&#xD;
&#xD;
          -  having an adverse reaction to methylphenidate, or other stimulant medication&#xD;
&#xD;
          -  having a contraindication to MRI&#xD;
&#xD;
          -  current smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin L Bigos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin L Bigos, PhD</last_name>
    <phone>4126140453</phone>
    <email>kbigos1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robyn Wiseman, BS</last_name>
    <phone>304-551-3309</phone>
    <email>rwisema5@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin L Bigos, PhD</last_name>
      <phone>412-614-0453</phone>
      <email>kbigos1@jhu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robyn L Wiseman, BS</last_name>
      <phone>3045513309</phone>
      <email>rwisema5@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

